Orthofix Medical Inc. (OFIX)
Nasdaq · Healthcare · Medical Devices
$9.50+4.51%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $384M
- Forward P/E
- 25.7
- 52-week range
- $8.50 – $16.99
- 52-week change
- −35.99%
- EPS (trailing)
- −$1.52
- Next earnings
- Nov 3, 2026
Fiscal year to Dec 2025
- Revenue
- $822M (+2.85%)
- Net income
- −$92.2M
- Operating margin
- −9.9%
- Diluted EPS
- −$2.33
- Free cash flow
- −$1.3M
From the company’s annual report on SEC EDGAR.
About Orthofix Medical Inc.
Orthofix Medical Inc., together with its subsidiaries, operates as a medical technology company in the United States, Italy, the United Kingdom, France, Germany, Brazil, and internationally. It operates through two segments, Global Spine and Global Limb Reconstruction. The Global Spine segment manufactures, distributes, and provides support services for bone growth stimulation devices that enhance bone fusion; designs, develops, and markets a portfolio of spine fixation implant products for use throughout the spinal column; and offers bone graft substitutes, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers in various forms with supporting graft delivery solutions to treat various spinal, orthopedic, and dental conditions. This segment also designs, develops, and markets a portfolio of navigation technologies, including tracked surgical tools, intelligent software, and imaging equipment based on machine-vision and optical innovations; and 7D FLASH Navigation System, a navigation platform for spinal and cranial procedures.
Headquarters: Lewisville, United States · 1,605 employees · orthofix.com